体外生命支持中标准剂量普通肝素与低剂量普通肝素及低分子肝素的比较(RATE):一项开放标签、随机、非劣效性试验
RATE试验在7个荷兰ICU纳入330例接受静脉-静脉或静脉-动脉ECMO、无全剂量抗凝绝对指征的成人,随机分为标准剂量静脉普通肝素(APTT为基线2.0–2.5倍)、低剂量静脉普通肝素(APTT为基线1.5–2.0倍)或治疗性皮下低分子肝素三组。6个月时复合主要终点(ECMO期间严重出血、严重血栓栓塞并发症或全因死亡)发生率:标准剂量组81%、低剂量组72%(绝对风险差−9.1个百分点,95%CI −20.3至2.1)、低分子肝素组75%(−6.1个百分点,95%CI −17.2至5.0),两种干预均达到非劣效(95%CI上限<7.5个百分点)。严重出血在低剂量组58%、低分子肝素组59%、标准剂量组65%,严重血栓栓塞并发症分别为10%、9%、11%,差异均未达统计学显著。作者认为该结果支持重新考虑ECMO抗凝目标。
要点
- ECMO成人患者中,低剂量静脉普通肝素(APTT基线1.5–2.0倍)6个月复合终点72% vs 标准剂量(2.0–2.5倍)81%,绝对风险差−9.1个百分点(95%CI −20.3至2.1),达到非劣效。
- 治疗性皮下低分子肝素6个月复合终点75% vs 标准剂量81%,绝对风险差−6.1个百分点(95%CI −17.2至5.0),达到非劣效。
- 严重出血:低剂量普通肝素58%、低分子肝素59%、标准剂量65%,差异未达统计学显著。
- 严重血栓栓塞并发症:低剂量普通肝素10%、低分子肝素9%、标准剂量11%,无过剩且差异未达统计学显著。
- 6个月死亡:标准剂量50%、低剂量42%、低分子肝素44%。
适用人群与场景
- 18岁及以上、在ICU接受静脉-静脉或静脉-动脉ECMO支持的成人。
- 无全剂量抗凝绝对指征(如机械二尖瓣)。
- 排除:有全剂量抗凝绝对指征者(如机械二尖瓣)。
诊断标准与关键阈值
- 标准剂量静脉普通肝素:活化部分凝血活酶时间为基线2.0–2.5倍。
- 低剂量静脉普通肝素:活化部分凝血活酶时间为基线1.5–2.0倍。
- 非劣效界值:绝对风险差95%CI上限<7.5个百分点。
处置流程与药物剂量
- 标准剂量组:静脉普通肝素,目标活化部分凝血活酶时间为基线2.0–2.5倍。
- 低剂量组:静脉普通肝素,目标活化部分凝血活酶时间为基线1.5–2.0倍。
- 低分子肝素组:治疗性皮下低分子肝素。
红旗征与不能漏的情况
- ECMO支持期间发生严重出血。
- ECMO支持期间发生严重血栓栓塞并发症。
研究设计与关键结果
- 开放标签、三臂、随机、非劣效性试验,7个荷兰ICU,2020年10月22日至2024年9月12日纳入330例,随机分为标准剂量静脉普通肝素110例、低剂量静脉普通肝素110例、治疗性皮下低分子肝素110例。
- 6个月时分析320例(男225例[70%]、女95例[30%],中位年龄56岁[IQR 45–65],白种人255例[80%])。
- 复合主要终点:标准剂量组87/107(81%)、低剂量组78/108(72%)(绝对风险差−9.1个百分点,95%CI −20.3至2.1)、低分子肝素组79/105(75%)(−6.1个百分点,95%CI −17.2至5.0),均达到非劣效。
- 严重出血:低剂量组63例(58%)、低分子肝素组62例(59%) vs 标准剂量组70例(65%),差异未达统计学显著。
- 严重血栓栓塞并发症:低剂量组11例(10%)、低分子肝素组9例(9%) vs 标准剂量组12例(11%),差异未达统计学显著。
- 6个月死亡:标准剂量组54例(50%)、低剂量组45例(42%)、低分子肝素组46例(44%)。
证据类型、等级与局限
- 研究类型:开放标签、三臂、随机、非劣效性试验。
- 非劣效界值:绝对风险差95%CI上限<7.5个百分点。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,低剂量普通肝素与治疗性低分子肝素非劣效于标准剂量普通肝素,该结果支持重新考虑ECMO抗凝目标。
- 作者认为,鉴于ECMO全球扩展,降低抗凝目标可能大幅减少出血相关伤害。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients receiving extracorporeal membrane oxygenation (ECMO), standard practice is full-dose intravenous unfractionated heparin (UFH) targeting an activated partial thromboplastin time of 2·0-2·5 times baseline to reduce thrombotic risk. This approach can increase bleeding without further reducing thrombosis compared with low-dose UFH. Robust evidence to guide anticoagulation targets is absent because anticoagulation targets in ECMO have never been assessed in a sufficiently powered randomised trial. We aimed to determine whether low-dose UFH or therapeutic low-molecular-weight heparin (LMWH) is non-inferior to standard-dose UFH in patients receiving ECMO.
METHODS: In this open-label, three-arm, randomised, non-inferiority trial at seven Dutch intensive care units (ICUs), adults aged 18 years or older supported with veno-venous or veno-arterial ECMO at the ICU without vital indication for full-dose anticoagulation (eg, mechanical mitral valve) were randomly assigned to intravenous standard-dose UFH (activated partial thromboplastin time 2·0-2·5 times baseline), intravenous low-dose UFH (1·5-2·0 times baseline), or therapeutic subcutaneous LMWH. The primary outcome was a composite of severe bleeding during ECMO support, severe thromboembolic complications during ECMO support, or all-cause mortality at 6 months, and was assessed in all randomly assigned patients with deferred informed consent and 6-month follow-up data according to the intention-to-treat principle. Non-inferiority was met if the upper 95% CI limit for the absolute risk difference was less than 7·5 percentage points. This trial is registered at ClinicalTrials.gov (NCT04536272) and the Dutch trial register (NL7976).
FINDINGS: Between Oct 22, 2020, and Sept 12, 2024, 330 patients were enrolled: 110 were randomly assigned to standard-dose UFH, 110 to low-dose UFH, and 110 to LMWH. Of 330 enrolled patients, 320 (225 [70%] males, 95 [30%] females; median age 56 years [IQR 45-65]; 255 [80%] White ethnicity) were analysed at 6 months. The composite primary outcome occurred in 87 (81%) of 107 patients with standard-dose UFH, 78 (72%) of 108 with low-dose UFH (absolute risk difference -9·1 percentage points [95% CI -20·3 to 2·1]), and 79 (75%) of 105 with LMWH (-6·1 percentage points [-17·2 to 5·0]), meeting non-inferiority for both interventions. The frequency of severe bleeding was lower with low-dose UFH and LMWH than with standard-dose UFH (63 [58%] patients and 62 [59%] vs 70 [65%]), without excess severe thromboembolic complications (11 [10%] and nine [9%] vs 12 [11%]), although these differences did not reach statistical significance. At 6 months, 54 (50%) patients in the standard-dose UFH group, 45 (42%) in the low-dose UFH group, and 46 (44%) in the LMWH group had died.
INTERPRETATION: Low-dose UFH and therapeutic LMWH were non-inferior to standard-dose UFH. This finding supports reconsideration of anticoagulation targets in ECMO. Given the global expansion of ECMO, these findings suggest that reduced anticoagulation targets could substantially reduce bleeding-related harm.
参考来源
- Minnen OV, Lansink-Hartgring AO, van Amstel RBE, et al. Standard-dose unfractionated heparin versus low-dose unfractionated heparin and low-molecular-weight heparin in extracorporeal life support (RATE): an open-label, randomised, non-inferiority trial. Lancet. 2026. PMID: 42413523. doi:10.1016/S0140-6736(26)00851-2
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。